Proficio Capital Partners LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

Proficio Capital Partners LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 163.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,425 shares of the biopharmaceutical company's stock after purchasing an additional 13,922 shares during the period. Proficio Capital Partners LLC's holdings in Pfizer were worth $568,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Clarity Asset Management Inc. acquired a new stake in Pfizer during the 4th quarter valued at approximately $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. purchased a new position in shares of Pfizer during the first quarter worth $28,000. Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter valued at $30,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer in the first quarter valued at $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE PFE traded down $0.57 during mid-day trading on Friday, hitting $24.79. The stock had a trading volume of 35,628,980 shares, compared to its average volume of 38,205,096. The firm's 50 day moving average is $24.30 and its 200 day moving average is $24.66. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a market capitalization of $140.91 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.94%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley upped their price objective on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.